- Home
- MRSN vs ICCC Comparison
MRSN vs ICCC Comparison
Compare MRSN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ICCC
- Stock Information
- Founded
- MRSN 2001
- ICCC 1982
- Country
- MRSN United States
- ICCC United States
- Employees
- MRSN N/A
- ICCC N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- ICCC Health Care
- Exchange
- MRSN Nasdaq
- ICCC Nasdaq
- Market Cap
- MRSN 47.1M
- ICCC 55.5M
- IPO Year
- MRSN 2017
- ICCC 1987
- Fundamental
- Price
- MRSN $27.87
- ICCC $5.50
- Analyst Decision
- MRSN Buy
- ICCC
- Analyst Count
- MRSN 5
- ICCC 0
- Target Price
- MRSN $30.38
- ICCC N/A
- AVG Volume (30 Days)
- MRSN 211.4K
- ICCC 18.5K
- Earning Date
- MRSN 11-14-2025
- ICCC 11-13-2025
- Dividend Yield
- MRSN N/A
- ICCC N/A
- EPS Growth
- MRSN N/A
- ICCC N/A
- EPS
- MRSN N/A
- ICCC 0.26
- Revenue
- MRSN $33,180,000.00
- ICCC $27,769,304.00
- Revenue This Year
- MRSN N/A
- ICCC N/A
- Revenue Next Year
- MRSN N/A
- ICCC N/A
- P/E Ratio
- MRSN N/A
- ICCC $20.92
- Revenue Growth
- MRSN N/A
- ICCC 16.49
- 52 Week Low
- MRSN $5.21
- ICCC $3.38
- 52 Week High
- MRSN $70.73
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- MRSN 89.87
- ICCC 34.25
- Support Level
- MRSN $7.59
- ICCC $5.95
- Resistance Level
- MRSN $28.07
- ICCC $6.36
- Average True Range (ATR)
- MRSN 0.69
- ICCC 0.24
- MACD
- MRSN 1.80
- ICCC -0.05
- Stochastic Oscillator
- MRSN 99.51
- ICCC 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.